CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
ongoing trials trial from www.clinicaltrials.gov

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis - Phase 2|Phase 3 - Not yet recruiting

  • Year: 2022
  • Date: September 2022
  • Author: Wake Forest University Health Sciences|Emory University|University of Minnesota|University of Texas Southwestern Medical Center
Source

https://ClinicalTrials.gov/show/NCT05408910

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment

Participants

Cystic Fibrosis|Abdominal Pain|Small Bowel Disease - 12 Years and older   (Child, Adult, Older Adult)

Interventions

Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]|Drug: Placebo

Outcome measures

Rifaximin Treatment Group Improvement of Symptoms|Improved ePROS scores

Keywords: Rifaximin; other anti-bacterial agents; Anti-Bacterial Agents; pharmacological_intervention;